RecruitingPhase 1NCT07433621
Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency
Studying X-linked lymphoproliferative disease due to XIAP deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Principal Investigator
- Rebecca Marsh, MDChildren's Hospital Medical Center, Cincinnati
- Intervention
- Quercetin(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 2 years · MALE
- Timeline
- 2026 – 2029
Study locations (1)
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07433621 on ClinicalTrials.gov